AAAAAA
Results:
1-23
|
Results: 23
Authors:
Bergman, I
Barmada, MA
Griffin, JA
Slamon, DJ
Citation: I. Bergman et al., Treatment of meningeal breast cancer xenografts in the rat using an anti-P185/HER2 antibody, CLIN CANC R, 7(7), 2001, pp. 2050-2056
Authors:
Vogel, C
Cobleigh, MA
Tripathy, D
Gutheil, JC
Harris, LN
Fehrenbacher, L
Slamon, DJ
Murphy, M
Novotny, WF
Burchmore, M
Shak, S
Stewart, SJ
Citation: C. Vogel et al., First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report, EUR J CANC, 37, 2001, pp. S25-S29
Authors:
Vogel, CL
Cobleigh, MA
Tripathy, D
Gutheil, JC
Harris, LN
Fehrenbacher, L
Slamon, DJ
Murphy, M
Novotny, WF
Burchmore, M
Shak, S
Stewart, SJ
Citation: Cl. Vogel et al., First-line Herceptin (R) monotherapy in metastatic breast cancer, ONCOL-BASEL, 61, 2001, pp. 37-42
Authors:
Slamon, DJ
Leyland-Jones, B
Shak, S
Fuchs, H
Paton, V
Bajamonde, A
Fleming, T
Eiermann, W
Wolter, J
Pegram, M
Baselga, J
Norton, L
Citation: Dj. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2., N ENG J MED, 344(11), 2001, pp. 783-792
Authors:
Aguilar, Z
Slamon, DJ
Citation: Z. Aguilar et Dj. Slamon, The transmembrane heregulin precursor is functionally active, J BIOL CHEM, 276(47), 2001, pp. 44099-44107
Authors:
Chan, KC
Knox, WF
Gandhi, A
Slamon, DJ
Potten, CS
Bundred, NJ
Citation: Kc. Chan et al., Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation, BR J SURG, 88(3), 2001, pp. 412-418
Authors:
Fejzo, MS
Slamon, DJ
Citation: Ms. Fejzo et Dj. Slamon, Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins, AM J PATH, 159(5), 2001, pp. 1645-1650
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts
Authors:
Strawn, LM
Kabbinavar, F
Schwartz, DP
Mann, E
Shawver, LK
Slamon, DJ
Cherrington, JM
Citation: Lm. Strawn et al., Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts, CLIN CANC R, 6(7), 2000, pp. 2931-2940
Authors:
Pauletti, G
Dandekar, S
Rong, HM
Ramos, L
Pong, HJ
Seshadri, R
Slamon, DJ
Citation: G. Pauletti et al., Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry, J CL ONCOL, 18(21), 2000, pp. 3651-3664
Authors:
Reynolds, CP
Wang, Y
Melton, LJ
Einhorn, PA
Slamon, DJ
Maurer, BJ
Citation: Cp. Reynolds et al., Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide, MED PED ONC, 35(6), 2000, pp. 597-602
Authors:
Pegram, MD
Lopez, A
Konecny, G
Slamon, DJ
Citation: Md. Pegram et al., Trastuzumab and chemotherapeutics: Drug interactions and synergies, SEMIN ONCOL, 27(6), 2000, pp. 21-25
Authors:
Konecny, G
Pegram, M
Untch, M
Thomssen, C
Janicke, F
Hepp, H
Slamon, DJ
Citation: G. Konecny et al., HER-2/neu as a predictive marker in breast cancer, GEBURTSH FR, 60(12), 2000, pp. 609-619
Authors:
Paquette, RL
Dergham, ST
Karpf, E
Wang, HJ
Slamon, DJ
Souza, L
Glaspy, JA
Citation: Rl. Paquette et al., Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer, BLOOD, 96(7), 2000, pp. 2385-2390
Authors:
Arboleda, MJ
Slamon, DJ
Citation: Mj. Arboleda et Dj. Slamon, Signal transduction - A technical overview, METH MOL M, 39, 2000, pp. 555-565
Authors:
Wilson, CA
Ramos, L
Villasenor, MR
Anders, KH
Press, MF
Clarke, K
Karlan, B
Chen, JJ
Scully, R
Livingston, D
Zuch, RH
Kanter, MH
Cohen, S
Calzone, FJ
Slamon, DJ
Citation: Ca. Wilson et al., Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas, NAT GENET, 21(2), 1999, pp. 236-240
Authors:
Aguilar, Z
Akita, RW
Finn, RS
Ramos, BL
Pegram, MD
Kabbinavar, FF
Pietras, RJ
Pisacane, P
Sliwkowski, MX
Slamon, DJ
Citation: Z. Aguilar et al., Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells, ONCOGENE, 18(44), 1999, pp. 6050-6062
Authors:
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648
Authors:
Oh, JJ
Grosshans, DR
Wong, SG
Slamon, DJ
Citation: Jj. Oh et al., Identification of differentially expressed genes associated with HER-2/neuoverexpression in human breast cancer cells, NUCL ACID R, 27(20), 1999, pp. 4008-4017
Authors:
Pegram, MD
Slamon, DJ
Citation: Md. Pegram et Dj. Slamon, Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity, SEMIN ONCOL, 26(4), 1999, pp. 89-95
Authors:
Lopez, AM
Pegram, MD
Slamon, DJ
Landaw, EM
Citation: Am. Lopez et al., A model-based approach for assessing in vivo combination therapy interactions, P NAS US, 96(23), 1999, pp. 13023-13028
Authors:
Pietras, RJ
Poen, JC
Gallardo, D
Wongvipat, PN
Lee, HJ
Slamon, DJ
Citation: Rj. Pietras et al., Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cellsoverexpressing this oncogene, CANCER RES, 59(6), 1999, pp. 1347-1355
Authors:
Paquette, RL
Gonzalez, E
Yoshimura, R
Tran, L
Choi, R
Baldwin, G
Slamon, DJ
Glaspy, J
Citation: Rl. Paquette et al., Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media, J HEMATOTH, 7(6), 1998, pp. 481-491
Authors:
Pegram, MD
Pauletti, G
Slamon, DJ
Citation: Md. Pegram et al., HER-2/neu as a predictive marker of response to breast cancer therapy, BREAST CANC, 52(1-3), 1998, pp. 65-77
Risultati:
1-23
|